PTGX: Protagonist Therapeutics Inc Price to Sales
Protagonist Therapeutics develops innovative oral therapies for blood and gastrointestinal disorders, replacing injections. This price-to-sales chart illustrates current trends, with the value holding around 15.90. High margins from synthesized patents provide an economy of scale. Business prospects rely on the success of rusfertide and strategic collaboration with major partners to generate royalties.
Protagonist Therapeutics Inc (PTGX) - metric breakdowns and financial figures
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Debt to Capital Protagonist Therapeutics|PTGX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Protagonist Corp|PTGX - Company Aggregate Debts|Debts to Book Capitalization Protagonist Therapeutics Inc|PTGX - Company Long-Term Debts|Short-Term Indebtedness Protagonist Therapeutics|Immediate Liquidity protagonist-inc.com
- earnings and valuation multiples indicators:
PTGX - Company Net Income|Net Profit Forecast Protagonist Therapeutics|PTGX - P/E Multiple|Market Cap to Projected Earnings Protagonist Therapeutics, Inc.|PTGX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Protagonist Therapeutics Inc|PTGX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Protagonist Therapeutics|PTGX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months protagonist-inc.com|PTGX - Net earnings per share growth this year|Projected earnings per share increase next year Protagonist Therapeutics
- total revenue and sales volume data:
General company analysis:PTGX protagonist-inc.com
The P/S ratio reflects the market value of a business relative to its sales volume, allowing investors to determine the extent of overpayment for an asset amid inflationary pressures. When analyzing the price-to-sales valuation on GURU.Markets, it is critical to consider that Protagonist Therapeutics (PTGX) expenditures on costly cold-chain peptide logistics impact margins, making this indicator key to monitoring capitalization efficiency.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA - Price-to-Revenue Ratio|Price-to-Sales Ratio IMVT|Kiniksa Pharmaceuticals (KNSA) - Price-to-Revenue Ratio|grifols.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Adaptive Biotechnologies Corporation|Price to Sales Celldex Therapeutics Inc CLDX|Market Cap to Revenue AUPH (Aurinia Pharma)|Market Cap to Sales Volume BCRX|P/S Multiple VERA (Vera Therapeutics, Inc.)|P/S Multiple dianthustx.com DNTH|Pharvaris - P/S Multiple|Price-to-Revenue Multiple AbCellera Biologics Inc. (ABCL)|Tourmaline Corp (TRML) - Price-to-Revenue Ratio|Price to Sales Precigen Corp (PGEN)|Price-to-Revenue Ratio Pharming Group N.V.|Market Cap to Revenue Ratio NKTR (nektar.com)|P/S Multiple UPB|Price-to-Revenue Coefficient Zenas Bio|Price-to-Revenue Ratio Immunome Corp IMNM|Price-to-Revenue Coefficient Gossamer Bio Corp. (GOSS)|KALV: Market Cap to Revenue|septerna.com - Market Cap to Sales Volume|PVLA (Pieris Pharmaceuticals, Inc.) - Market Cap to Revenue|Savara Inc - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue RIGL|ANAB (AnaptysBio Inc.) - Market Cap to Sales Volume|P/S Multiple ATXS|ENGN (engene.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple RAPT (RAPT Therapeutics)|Aerovate Therapeutics, Inc. (JBIO) - Price to Sales|ACRS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio KYTX (Kyverna Therapeutics, Inc)|TLSA: P/S Multiple|cabalettabio.com (CABA) - P/S Multiple|Price-to-Revenue Ratio Ventyx Biosciences, Inc.|Theratechnologies, Inc. - Price-to-Sales Ratio|P/S Multiple AVTX|ELDN - Price to Sales|Agenus - Market Cap to Revenue|P/S Multiple climbbio.com CLYM|ZURA: Market Cap to Revenue|aTyr Pharma Inc - Market Cap to Sales Volume|ADAG: P/S Multiple|IMA - Price-to-Revenue Coefficient|STTK (Shattuck Labs Inc) - P/S Multiple|Market Cap to Revenue Equillium Bio (EQ)|Price-to-Revenue Ratio Connect Biopharma (CNTB)|Price-to-Revenue Coefficient immunic-therapeutics.com|Price-to-Revenue Ratio Atara Bio ATRA|IFRX (InflaRx NV) - Price-to-Sales Ratio|XFOR: Market Cap to Revenue|Adicet Bio - Market Cap to Sales Volume|CELU: P/S Multiple|Price-to-Revenue Multiple INmune Bio Inc INMB|Market Cap to Revenue BRNS|Market Cap to Revenue Ratio KZR (Kezar Life Sciences Inc)|Price-to-Revenue Ratio SAB Biotherapeutics (SABS)|AKTX: Price-to-Sales Ratio|P/S Multiple ENLV (Enlivex Therapeutics Ltd.)|Market Capitalization-to-Revenue Ratio QTTB|GeoVax Labs Inc - P/S Multiple|EDSA - P/S Multiple|iBio, Inc. (IBIO) - Price-to-Revenue Ratio|Carisma Therapeutics Inc. - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio XTL Biopharmaceuticals Ltd.|Market Cap to Revenue Bolt Bio (BOLT)|P/S Multiple HCWB|P/S Multiple aptevotherapeutics.com (APVO)|AIM ImmunoTech Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ADTX|GRI Bio - P/S Multiple|Price-to-Revenue Coefficient XORTX Therapeutics Inc XRTX|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Revelation Biosciences Corp|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue scinai.com (SCNI)|Market Cap to Revenue CALI (CalciMedica, Inc.)|P/S Multiple affimed.com (AFMD)|Price-to-Revenue Ratio Allakos ALLK|HOOK: Market Cap to Revenue Ratio|IGM Bio - P/S Multiple|Price to Sales iteostherapeutics.com|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Price-to-Sales Ratio TCBP (TC BioPharm (Holdings) Plc)|Price-to-Revenue Ratio Third Harmonic Bio, Inc
